Severe Immune Checkpoint Inhibitor Toxicity Leading to ICU Admission in Patients With Solid Tumors

Marine Leprince^{1

2}, Bertrand Pourroy^{2

3}, Mohamed Boucekine^{2

4}, Pascale Tomasini^{2

5

6}, Julien Carvelli^{1

2

6}

Affiliations

¹ AP-HM, Réanimation des Urgences.
² Aix-Marseille University.
³ AP-HM, OncoPharma Unit.
⁴ AP-HM, Timone University Hospital Département de Santé Publique et d'Information Médicale.
⁵ AP-HM, Nord University Hospital Multidisciplinary Oncology & Therapeutic Innovations Department.
⁶ AP-HM, OncoSafety Network, Marseille, France.

Marine Leprince et al. Am J Clin Oncol. 2022.

. 2022 Sep 1;45(9):403-404.

doi: 10.1097/COC.0000000000000935. Epub 2022 Aug 26.

Marine Leprince^{1

2}, Bertrand Pourroy^{2

3}, Mohamed Boucekine^{2

4}, Pascale Tomasini^{2

5

6}, Julien Carvelli^{1

2

6}

¹ AP-HM, Réanimation des Urgences.
² Aix-Marseille University.
³ AP-HM, OncoPharma Unit.
⁴ AP-HM, Timone University Hospital Département de Santé Publique et d'Information Médicale.
⁵ AP-HM, Nord University Hospital Multidisciplinary Oncology & Therapeutic Innovations Department.
⁶ AP-HM, OncoSafety Network, Marseille, France.

No abstract available

Conflict of interest statement

The authors declare no conflicts of interest.

1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
1. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N Engl J Med. 2020;383:1328–1339.
1. Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89.
1. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–1768.
1. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563–580.